Full Year 2023 Investor Presentation

Solid operating profit growth driven by Diabetes care 143 Investor presentation Full year 2023 Novo NordiskⓇ Operating profit Operating profit split by franchise DKK billion 11% 3% 8% 28% 37% Percent of sales 6% 7% 13% 15% 44% 120 60% 3% 19% 100 60 80 60 60 40 40 20 20 0 2019 2020 Operating profit Operating profit as % of sales CER: Constant exchange rates 40% 97% 81% 20% 2023 Diabetes and Obesity care Rare disease 0% 2021 2022 2023 2019 Reported operating profit growth Operating profit growth at CER

View entire presentation